- Home
- ELUT vs IGC Comparison
ELUT vs IGC Comparison
Compare ELUT & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELUT | IGC |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.6M | 32.0M |
| IPO Year | 2020 | 2005 |
Fundamental Metrics
Financial Performance| Metric | ELUT | IGC |
|---|---|---|
| Price | $0.85 | $0.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 73.7K | ★ 493.1K |
| Earning Date | 11-05-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 146.77 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,293,000.00 | $1,271,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.50 | $0.08 |
| 52 Week High | $1.39 | $0.39 |
Technical Indicators
Market Signals| Indicator | ELUT | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 52.80 | 34.92 |
| Support Level | $0.75 | $0.08 |
| Resistance Level | $0.87 | $0.30 |
| Average True Range (ATR) | 0.07 | 0.02 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 74.04 | 68.76 |
Price Performance
Historical ComparisonAbout ELUT Elutia Inc.
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.